Efficacy ResultsCingulate recently reported positive efficacy results from its pediatrics study for CTx-1301, highlighting its potential in ADHD treatment.
Market PotentialCingulate's focus on ADHD presents a large market potential, as ADHD affects millions of children, adolescents, and adults.
Regulatory ProgressFDA suggests Cingulate may file NDA for CTx-1301 with existing data, indicating sufficient data is already available for submission.